Boston Biomedical

Boston Biomedical, Inc. is a fully integrated oncology biotechnology company founded in November 2006 and wholly owned by Sumitomo Dainippon Pharma Co., Ltd. The company's mission is to develop the next generation of cancer therapeutics by targeting cancer stemness pathways — the mechanisms that sustain cancer stem cells and drive tumor recurrence and metastasis. Its lead compound napabucasin (BBI608) is an orally administered STAT3 inhibitor that has advanced into multiple global Phase 3 clinical trials across colorectal, pancreatic, and other cancers, alongside amcasertib (BBI503), making Boston Biomedical an industry leader in cancer stem cell pathway inhibition.